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Molecular diagnostics provide a powerful method to detect and diagnose various
neurological diseases such as Alzheimer’s and Parkinson’s disease. The confirmation
of such diagnosis allows early detection and subsequent medical counseling that
help specific patients to undergo clinically important drug trials. This provides a
medical pathway to have better insight of neurogenesis and eventual cure of the
neurodegenerative diseases. In this short review,wepresent recent advances inmolecular
diagnostics especially biomarkers and imaging spectroscopy for neurological diseases.
We describe advances made in Alzheimer’s disease (AD), Parkinson’s disease (PD),
Amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD), and finally present a
perspective on the future directions to provide a framework for further developments and
refinements of molecular diagnostics to combat neurodegenerative disorders.
Keywords: biomarkers, miRNAs, Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis,
Huntington’s disease, neurodegeneration, neurons
Introduction
Neurodegenerative disorders correspond to the disorders in the central nervous system that are
characterized by the progressive loss of neural tissues. Changes in the neurons cause them to
function abnormally and eventually result in the cells’ demise. The reason is the inability of
the neurons to regenerate on their own after the neural deterioration or severe damage. At
present, roughly around 5 million Americans suffer from Alzheimer’s disease (AD); 1 million
from Parkinson’s disease (PD); 400,000 from multiple sclerosis (MS); 30,000 from Amyotrophic
lateral sclerosis (ALS), and 3000 from Huntington’s disease (HD). The incidence is expected
to soar as the population ages, because neurodegenerative diseases strike primarily in mid-to
late-life. Neuroregeneration is a viable way to curb neurodenegerative disorders. One of the current
approaches is stem cell therapy that has shown to be potentially helpful in neuroregeneration or
even neuronal cell replacement (Chung et al., 2002; Rachakonda et al., 2004).
An early detection of the onset of neurodegeneration is vital as it can provide a chance for an
early treatment that may be helpful to prevent further progression of the disease. Among current
diagnostics, neuropathology is considered as the gold standard (Chung et al., 2002). However, it is
usually based on an autopsy that is done after the death of a patient. Therefore, medical researchers
are in search for an effective non-invasive diagnostic method that can be employed for an early
detection of neurodegeneration when a pharmacological intervention is still possible.
Molecular diagnosis has emerged as a powerful technique that can be helpful for an early
detection of various neurodegenerative disorders. One of the powerful molecular diagnostics is the
application of biomarkers. Biomarkers are basically biological molecular substances that are used
to indicate the presence or onset of a certain disorder. Normal and abnormal biological processes
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can be detected by the use of biomarkers. The principal
requirement for a good biomarker is its preciseness and
reliability. It should also be able to distinguish between the
healthy and the diseased tissues, and should differentiate between
different diseases. Biomarkers are considered promising in aiding
in early diagnosis and setting standards for the development
of new remedies to treat neuronal disorders (Chung et al.,
2002; Peterson, 2002; Rachakonda et al., 2004). Biomarkers
may be measured using imaging techniques such as positron
emission tomography (PET), magnetic resonance imaging
(MRI), and nuclear magnetic resonance spectroscopy (NMRS).
Table 1 summarizes various molecular diagnostic markers for
neurodegenerative diseases.
Among other recently developed molecular diagnostics,
biomarkers coupled with magnetic resonance spectroscopy
(MRS) has shown promise. It is a quantitative imaging technique
that allows in-vivo measurement of certain neuronal metabolites
as biomarkers that can be used to study metabolic dysfunctions
TABLE 1 | A summary giving genetic and biochemical diagnostic markers
for Alzheimer’s, Parkinson’s, Amyotrophic lateral sclerosis, and
Huntington’s Disease.
Diseases Genetic diagnostic markers Biochemical
diagnostic
markers
Alzheimer’s
Disease (AD)
Amyloid precursor protein mutations Plasma/CSF
Aβ1−42 peptide
Presinilin-1 gene mutations CSF tau protein
Presinilin-2 gene mutations Phospho-tau
ApoE isoforms
ApoEpolymormisms
Parkinson’s
Disease (PD)
α-synuclein gene mutations Loss of Dopamine
transporter (DAT)
Parkin gene mutations Lewy bodies
UCH-L1 gene mutations
PINK1 gene mutations
DJ-1 gene mutations
NR4A2 gene mutations
Amyotrophic
Lateral Sclerosis
(ALS)
ALS2 gene mutations mGLUR2
NEFH gene mutations SOD1
SOD1 gene mutation Glutathione
C9orf72 gene mutation 8OH2′dG
FUS gene mutation Cytokines
TARDBP gene mutations
Huntington’s
Disease (HD)
HTT gene mutations Growth hormones
Cytokines
mGLUR2
SOD1
Glutathione
8OH2′dG
and irreversible neuronal damage (Ciurleo et al., 2014). The
potential role of MRS as an in-vivomolecular imaging biomarker
was investigated for early diagnosis of PD and for monitoring the
efficacy of therapeutic interventions (Ciurleo et al., 2014).
Altered expression of microRNAs (miRNAs) in many disease
states, including neurodegeneration along with applications of
miRNAs in biological fluids in different pathologies make them
promising candidates as neurodegenerative disease biomarkers
that may lead to identify new therapeutic targets (Grasso
et al., 2014). The role of miRNAs in the pathogenesis of
neurodegeneration was investigated to gain insights into the
possibilities and challenges of using these small RNA molecules
as a signature for neurodegenerative conditions (Grasso et al.,
2014). It is known that miRNAs can be transported by
exosomes which are small membrane-derived vesicles secreted by
many cell types, including neurons, astrocytes, oligodendrocytes,
and microglia (Lachenal et al., 2011; Russo et al., 2012).
Exosomes shed from stimulated blood cells and the vascular
endothelium are involved in neurological disorders (Soreq et al.,
2013). Exosomes have significant potential as biomarkers for
disease diagnosis, as their molecular composition reflects the
physiological or pathophysiological changes in their cell of origin
(Lin et al., 2015). Furthermore, they can be isolated from biofluids
such as blood and urine, making them very attractive targets
for diagnostic application. It has been reported that exosomal
amyloid peptides accumulate in the brain plaques of AD patients
(Rajendran et al., 2006) and tau phosphorylated at Thr-181, an
established biomarker for AD, is present at elevated levels in
exosomes isolated from cerebrospinal fluid specimens of AD
patients with mild symptoms (Saman et al., 2012). Studies have
also shown release of α-synuclein in exosomes in an in vitro
model system of PD (Alvarez-Erviti et al., 2011). These exosomal
proteins may have great potential in clinical diagnostics and
should be further explored, as the concept is still new in the
biomarker discovery arena (Miller and O’Callaghan, 2015).
The research field of molecular diagnostics in
neurodegenerative disorder is still a nascent area of research
and development. It is anticipated that further developments
in various molecular diagnostics would pave the way for the
early detection and effective treatment of neurodegeneration.
In this short review, we focus on recent advances made in
major neurodegenerative disorders—AD, PD, ALS, and HD
and the applications of molecular diagnosis for the potential
remedies. We also present a perspective on the future direction
of diagnostics and curbing the progression of neuronal disorders.
Molecular Diagnosis for
Neurodegenerative Diseases: A Potentially
Better Approach Over Behavioral
Symptoms Based Diagnosis
Behavioral symptoms can be utilized for the pre-mortem
diagnosis of neurodegenerative disorders. However, the major
drawback of behavioral symptoms based diagnosis is its
limitations to identify patients early in the course of their disease,
when the pharmacological intervention can significantly prevent
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further progression of the disease, if detected early. For example,
well-established behavioral tests like the ADAS-Cog that are
regarded as the “gold-standard” for AD diagnosis may give false-
negative results for patients with mild symptoms (Posner et al.,
2013).
To overcome these diagnostics challenges, current neuro-
pathologic methods have been combined with molecular
biology techniques that have led to increased understanding
of neurodegenerative disorders along with biologically based
classifications of these disorders. Molecular diagnostics provide
a powerful tool in the diagnosis of many neurological diseases.
For example, genetic testing of mutations in disease-causing-
genes has been leveraged to define and classify many of the
heterogeneous inherited neurodegenerative syndromes (Gasser
et al., 2001a,b, 2003). Changes in pathologies, biochemistries
and genetics of patients can give us comprehensive information
regarding the nature of a particular disease. However, molecular
testing may be performed only after careful consideration and
a genetic counseling. We describe in the following sections
major neurologic disorders, and the ability and applications of
molecular diagnostics in their detection.
Alzheimer’s Disease
AD is the most common neurodegenerative disease in most
Countries; it is a progressive, degenerative disorder that attacks
the brain’s neurons, resulting in loss of memory, thinking
and language skills, and behavioral changes. Most of the
neurons that degenerate in this disease communicate with other
neurons using the chemical or neurotransmitter acetylcholine
in the brain. Alterations in acetylcholinesterase (AChE) and
butyrylcholinesterase (BuChE) can be observed in AD but
acetylcholine depletion is the most common and striking of all
symptoms (Rachakonda et al., 2004).
The two types of abnormal lesions that clog the brains of
Alzheimer’s patients are extracellular senile plaques (composed
of beta-amyloid peptides) and intracellular neurofibrillary tangles
(NFTs, composed of tau protein). Aβ forms as a result of
enzymatic cleavage of the parent Amyloid Precursor Protein
(APP). Proteases that are involved in the breakdown of APP, are
α-, β-, and γ- secretases (Hardy and Selkoe, 2002; Rachakonda
et al., 2004). The NFTs account for the synaptic degeneration or
the atrophy of nerve cells following damage to the synaptically
connected axons. NFTs are composed of paired helical filaments
(PHF), which are principally made up of hyperphosphorylated
insoluble form of tau protein (el-Agnaf and Irvine, 2002).
Diagnosis of AD is usually based on clinical observations
and cognitive testing like neuropsychological testing which
helps in the diagnosis and treatment of conditions like AD
that affect emotion, thinking and behavior (Harvey, 2012).
Neuropsychological tests accompany a comprehensive interview
with the patient, and include tests to assess attention, memory,
language, the ability to plan and reason, and modify behavior, as
well as assessments of personality and emotional stability, that
can also help the doctor and family better understand the impact
of a disorder on a patient’s everyday functioning. The disease is
eventually confirmed by postmortem by demonstrating amyloid
plaques and neurofibrillary tangles in the brain. However, the
progression of the disease process is an ongoing phenomenon
that significantly damages the brain long before clinical findings
appear. Hence, molecular biologists, biomedical, and medicine
experts and biotechnologists are coming together to design and
develop advanced diagnostic molecular markers that might allow
very early-stage diagnosis of AD and the objective assessment of
its responses to putative treatments (Rachakonda et al., 2004).
Several genetic and biochemical diagnostic biomarkers have been
employed to detect and diagnose AD.
Genetic Biomarkers
Less than 5% of all cases of AD can be accounted for bymutations
in the following three genes. Amongst them, mutations on
the two homologous presenilin genes: presenilin 1 (PS1, MIM
104 311) located on chromosome 14, and presenilin 2 (PS2,
MIM 600 759) located on chromosome 1, are most common
and are responsible for over half of the known familial AD
cases, whereas mutations in the gene for amyloid precursor
protein (APP, MIM 104 760) located on chromosome 21) are
comparatively less (Gasser et al., 2001a; Rachakonda et al., 2004).
The presenilin genes code for proteins known as presenilin,
which control the APP proteolysis into smaller peptides (Goodall
et al., 2013). An abnormal increase in the activity of APP can be
due to any missense mutation on one of these presenilin genes
resulting into more Aβ peptides (Berezovska et al., 2003). The
first genetic mutation linked to AD was found on the βAPP
gene (Rachakonda et al., 2004). This βAPP gene, encodes a
glycosylated trans-membrane protein which contains 770 amino
acids in its longest isoform. This was confirmed by the fact
that patients with Down’s syndrome also developed similar
plaques and suffered Alzheimer encephalopathy in their later
years (Rachakonda et al., 2004). In addition to the mutations
mentioned above, which can cause AD, the E4 allele of the ApoE
is associated with the sporadic forms of AD (Bekris et al., 2010).
Although E4 allele was detected in about 40–50% of all AD
patients, but could not serve as a diagnostic marker based on the
sensitivity criteria for biomarkers. Therefore, ApoE is regarded as
a risk factor indicator rather than an actual genetic marker of AD.
Along with positive family history, an early onset (in the 40s and
50s) which is common to all these monogenic forms, should act
as an indication for molecular genetic diagnosis.
Biochemical Markers
The levels of tau protein and Aβ in cerebrospinal fluid (CSF)
are the two most promising biochemical markers of AD. Aβ
is secreted into the extracellular space and biological fluids,
including CSF making Aβ42 a considerable indicator of AD
(Sunderland et al., 2003). A decrease in levels of Aβ in CSF
reflects AD and its sensitivity is around 80–90%. As AD
progresses Aβ peptide from CSF aggregates to form plaques
in the brain, thereby, lowering its concentration in the CSF.
CSF-Aβ42 appears to be a remarkable biomarker for diagnosis
of AD when used in combination with other AD biomarkers.
CSF-tau also provides a very high sensitivity for AD but
the reason for its abnormal increase in AD patients is not
clear. The combination of both CSF-Aβ42 and CSF-tau may
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improve their specificity and sensitivity and can be an ideal
biochemical marker set for AD (Sjögren et al., 2003). 2-(1-{6-
[(2-[18F] Fluoroethyl) (methyl)amino]-2-naphthyl}ethylidene)
malononitrile ([18F]FDDNP)-PET can determine the localization
and load of neurofibrillary tangles and senile amyloid plaques in
the human brain because of its ability to cross the Blood-Brain-
Barrier (BBB). FDG-PET is used to measure the brain’s energy
utilization and to infer synaptic number (Wurtman, 2015).
Therefore, PET Molecular imaging is employed to diagnose AD
(Rachakonda et al., 2004; Sair et al., 2004). This discovery of a
new binding site to Aβ40 fibrils as a result of FDDNP binding
provides a new opportunity for early treatment of AD. The
clinical sensitivity for AD using the “probable AD” category is
66 ± 17% relative to neuropathologically conformed diagnoses
and can be increased to 90.5 ± 5.5%, by including “possible
AD” patients at the expense of specificity. The sensitivity of 18F-
FDG PET is 91 ± 3% (Bokde et al., 2011). The combined use of
the [18F]FDDNP-PET molecular diagnostic labeling system and
other diagnostic tests provide a new pathway to early diagnosis
of AD (Sair et al., 2004; Wurtman, 2015). In a related work
employing imaging spectroscopy, SPECT and PET tracers were
used in the diagnosis and investigation of AD. Most tracers
demonstrate the neuronal loss associated with the condition and
results in regional decrease in glucose utilization which can be
studied with 18F-FDG PET imaging (Young, 2009). SPECT and
PET imaging are far more sensitive with the ability to detect
tracers at 10−9–10−11 mol/L, at concentrations of tracers that will
not disturb normal function (Bokde et al., 2011).
MicroRNAs (miRNAs) have been employed for early
detection of AD (Grasso et al., 2014). miRNAs belong to a family
of short, single-stranded 21–22 nucleotides-long non-coding
RNAs that constitute about 1% of all human genes. They
represent the most abundant class of small RNAs in animals.
Further, miRNAs are found in high abundance within the
nervous system, where they often replicate a brain-specific
expression pattern and are usually found to be co-expressed
with their targets. Their main roles are as key regulators of
different biological functions including synaptic plasticity and
neurogenesis, where they channelize the cellular physiology
toward neuronal differentiation. Also, they can indirectly
influence neurogenesis by regulating the proliferation and
self-renewal of neural stem cells (Grasso et al., 2014).
It is interesting to note that miRNAs are deregulated in several
neurodegenerative diseases, a spectrum of etiologies culminating
in a final common pathway of neuronal cell death (Goodall
et al., 2013). The dysfunction of miRNAs in neurodegenerative
disorders can be leveraged for early diagnosis of AD, which is
a novel approach to understanding neurodegenerative diseases
(Goodall et al., 2013). Further, the use ofmiRNAs as biomolecular
diagnostics markers has some advantages: first of all they allow
ease of detection with extreme specificity. Furthermore, unlike
large RNA molecules as mRNAs, miRNAs can be well preserved
in formalin, paraffin embedded tissues (FFPE) and also in
fresh snap-frozen specimens (Xi et al., 2007; Grasso et al.,
2014).
Mild cognitive Impairment (MCI) is an intermediate state
between normal aging and AD (and other dementias), which
is usually defined as the first stage when clinical symptoms
become evident (DeCarli, 2003). Plasma miRNA biomarkers
were reported to detect MCI, where an initial pool of miRNAs
was selected among known brain- and neuron-enriched miRNAs
(Sheinerman et al., 2012). The researchers then identified
biomolecular diagnostic marker pairs represented by two sets:
the “miR−132 family” that consist of miR−128/miR−491−5p,
miR−132/miR−491−5p and miR−874/miR−491−5p and
the “miR−134 family” comprising miR−134/miR−370,
miR−323−3p/miR−370 and miR−382/miR−370 with fairly
high sensitivity and specificity at 79–100% and 79–95%,
respectively. In a separate longitudinal study, the identified
miRNA biomolecular diagnostic marker pairs successfully
detected MCI in majority of patients at asymptomatic stage 1–5
years prior to clinical diagnosis (Sheinerman et al., 2012; Grasso
et al., 2014).
Recent observations were made related to change in the levels
of plasma phospholipids; that can be leveraged for developing
new bimolecular diagnostic marker for AD. The reduction in
the level of phospholipids is anticipated to enable the accurate
prediction, that whether a cognitively normal individual is going
to develop MCI or AD within 2 years (Wurtman, 2015). There
is one study on blood-based biomarker panel for detecting
preclinical AD with above 90% accuracy greater than that
obtained from most published CSF studies (Mapstone et al.,
2014).
Parkinson’s Disease
The search for molecular diagnostics biomarkers in PD is
critical to identify the disease in early stages which will allow
monitoring the effectiveness of neuroprotective therapies for PD
(Molochnikov et al., 2012). In PD, degeneration of neurons, more
specifically dopaminergic neurons between the substantianigra
(SN) and the striatum occur. As a result, a great majority
of dopamine producing cells in the substantianigra are lost
in patients with PD. The symptoms of PD are trembling in
hands, arms, legs, and face; stiffness of the limbs and trunk;
slowness of movement; and impaired balance and coordination.
As these neurons are progressively destroyed, patients may have
difficulty walking, talking and completing other simple tasks
(Rachakonda et al., 2004). PD usually affects people over the age
of sixty.
Currently, only clinical criteria are employed to diagnose
PD (Molochnikov et al., 2012). The evaluation of the clinical
status and evolution of PD are based on various factors
and medical steps. These include examination of symptoms,
utilizing structured scoring systems [Unified Parkinson’s
Disease Rating Scale, (UPDRS), Short Parkinson Evaluation
Scale, (SPES), Scales for Outcomes in Parkinson’s diseases—
(SCOPA), and the Hoehn and Yahr (H&Y) staging scale;
(Molochnikov et al., 2012)]. Clinical criteria based diagnosis
of PD can be done with a typical presentation and positive
response to levodopa with a sensitivity of 93%. However, the
major limitation of this technique is differential diagnosis
from other entities presenting Parkinsonism [e.g., essential
tremor, progressive supranuclear palsy (PSP), multisystem
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atrophy (MSA), corticobasal degeneration (CBD)] that may be
challenging.
Recent research has shown that molecular diagnostic tools can
be leveraged to overcome the current challenges on limitations to
early detection and effective differential diagnosis. A molecular
diagnostic signature in blood that identifies early PD was
reported. An assessment was done on whether a gene signature
could be detected in blood from early/mild PD patients that
could support the diagnosis of early PD, focusing on genes
found particularly altered in the substantianigra of sporadic
PD (Molochnikov et al., 2012). The research findings provide
evidence on the ability of a five-gene panel to diagnose
early/mild PD, with a possible diagnostic value for detection
of asymptomatic PD before overt expression of the disorder
(Molochnikov et al., 2012).
This pilot study demonstrated that the blood gene model
can have strong predictive value for PD diagnosis that possibly
may help to identify individuals at presymptomatic stages
(patients with depression, sleep disturbances or hyposmia or
patients carrying genetic risk factors) that are good candidates
for neuroprotective treatment. Such a biomolecular diagnostic
marker for PD can be of tremendous value for the identification
of a pathophysiological subgroup of PD patients that may
respond favorably to agents targeting the mechanisms reflected
by the gene panel.
Genetic Biomarkers
PD is inherited in a Mendelian autosomal dominant or
autosomal recessive fashion in a small number of families.
Mutations were found in α-synuclein (SNCA) and leucine-rich
repeat kinase2 (LRRK2) genes for late-onset disease and parkin
(PARK2), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1),
PTEN Induced Putative Kinase1 (PINK1), oncogene DJ1 (DJ1)
for early onset (Grasso et al., 2014).
Point mutations, duplications, and triplication in the α-
synuclein gene, which is located on chromosome 4, are a
characteristic of PD and they occur in most forms including
the rare early onset familial form of PD. Genes and gene
products have been identified by characterizing the monogenetic
autosomal dominant forms of PD. Several gene products of
the mutated genes in the autosomal dominant forms have
been linked to mitochondrial dysfunction, oxidative stress, and
mishandling of impaired or aberrant forms of the gene products
(e.g., oligometric α-synuclein) (Miller and O’Callaghan, 2015).
More than 70 mutations on the large parkin gene have been
associated with the early-onset form of Parkinsonism. Mutations
in the parkin gene may account for PD in as many as 50%
of familial cases of autosomal recessive juvenile Parkinsonism
(Pankratz et al., 2003). Another gene ubiquitin carboxy-terminal
hydrolase L1 (UCH-L1) located on chromosome 4 encodes
a protein which belongs to the family of deubiquitinating
enzymes. Protein UCH-L1 constitutes 1% of brain protein
and its function is presumed to act to recycle ubiquitin by
hydrolyzing the ubiquitinated peptides. This enzyme plays a
role in modifying the damaged proteins that might otherwise
accumulate to toxic levels in the neuron (Leroy et al., 1998).
Also two homozygous mutations in PINK1 gene associated
with PD were found in Spanish and Italian families. This
finding provided additional evidence that PINK1 mutations
are associated with PARK6 (Valente et al., 2004). And the
mutations associated with PARK7 are in DJ-1 gene (Bonifati
et al., 2003). Evidence suggests DJ-1 protein involvement in
oxidative stress and neurodegeneration. Slow progression of
symptoms with sustained response to levodopa treatment is
the clinical characteristics of DJ-1 Parkinsonism (Dekker et al.,
2003). Revealing the physiological role of these genes may
promote the understanding of the mechanisms of brain neuronal
maintenance.
Biochemical Markers
Two other major biomolecular diagnostic markers have been
employed to recognize the onset of PD. They include (1) the loss
of the dopamine transporter “DAT” detected by PET imaging
and (2) the presence of the α-synuclein protein located in the
Lewy body lesions. DAT mediates uptake of dopamine (DA)
into dopaminergic neurons by an electrogenic, Na+- and Cl−-
transport-coupledmechanism. DA and cocaine (uptake blockers)
would bind to both the shared and separate domains on the
transporter, which is observed to be dramatically influenced by
the presence of cations. DAT is also involved in the uptake of
toxins generating Parkinson’s syndrome. Thus, the localization of
striatal, preferentially putamen DAT concentration is considered
a high sensitivity parameter for the detection of early phases of
PD and best molecular diagnostic marker (Marek et al., 2000;
Rachakonda et al., 2004; Shinto et al., 2014). Discovery of Lewy
bodies and Lewy neuritis, the characteristic lesions in brains
of patients with PD and dementia is due to two mutations
in α-synuclein gene. Given that α-synuclein is also found in
other synucleinopathies, it should be used with the aid of other
diagnostic methods to increase the specificity and sensitivity for
PD (Duyckaerts and Hauw, 2003).
Several imaging techniques have been employed for the
diagnosis of PD, for example, PET with [18F]-Dopa tracer (Loane
and Politis, 2011) and single photon emission tomography
(SPECT) with [123I]-β-CIT (Tissingh et al., 1997). PET is
considered to be the most useful tool for PD diagnosis by
measuring the emission of positrons from the brain after a small
amount of radioactive isotopes or tracers have been injected
into the blood stream. Studies have shown a mean reduction of
40% in striatal 18F-Dopa uptake between controls and patients
with PD (Bokde et al., 2011). PD patients related to medication
typically have normal 18F-Dopa distribution. Tracer [18F]-Dopa
has very limited clinical availability but Ioflupane Iodine-123
(DatSCAN) is a widely available SPECT tracer which models
the presynaptic dopamine receptor (DaT) system. SPECT only
differ to PET in that it uses isotopes with longer half-lives
that can be stored on site (Rachakonda et al., 2004; Young,
2009). Recently a SPECT imaging with 99mTc-TRODAT-1 was
conducted in 16 consecutive PD patients (9 men; 7 women)
and in 6 age matched healthy volunteers (4 men; 2 women;
Shinto et al., 2014). The images were obtained 3 h after the
intra-venous injection of the tracer. A stepwise reduction in
specific striatal uptake of 99mTc-TRODAT-1 was found with
increasing disease severity between healthy controls vs. Stage
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I vs. Stage II vs. Stage III in PD patients (i.e., 3.77 vs. 2.56
vs. 1.57 vs. 0.63, P < 0.05). 99mTc-TRODAT-1 is accurate
and widely available for the assessment of DAT activity. These
techniques could improve differential diagnosis of Parkinsonism,
but cost-effectiveness remains a problem (Jankovic et al., 2000;
Molochnikov et al., 2012).
Biological fluids are excellent source for biomarkers as their
close proximity to cells reflects their biological condition and
are simple to obtain and cost-effective (Shinde et al., 2015).
With the increasing relevance of miRNAs in biofluids the
development of circulating biomarkers for PD has great potential.
A study using qRT-PCR suggested that in peripheral blood the
expression levels of miR-1, miR-22-5p, and miR-29 allow to
distinguish PD patients from healthy subjects, and also miR-16-
2-3p, miR-26a-2-3p, and miR30a differentiate between treated
and untreated patients (Margis et al., 2011). In a recent study
using next generation sequencing for total blood leukocytes it was
found that, 16 miRNAs including miR-16, miE-20a and miR-320
significantly altered in PD patients compared to healthy controls
(Soreq et al., 2013; Grasso et al., 2014).
There is no standard diagnostic test for Parkinson’s.
Researchers are still working to develop an accurate “biological
marker,” such as a blood test or an imaging scan. To date, tests
consist of specialized brain scanning techniques to measure the
dopamine system and brain metabolism is the best objective test
for PD (Torrent et al., 2015). But these tests are expensive and
performed only in specialized imaging centers.
Amyotrophic Lateral Sclerosis
ALS is a rapidly progressive, invariably fatal neurological disease
that attacks the neurons responsible for controlling voluntary
muscles. Messages from motor neurons in the brain (called
upper motor neurons) are transmitted to motor neurons in
the spinal cord (called lower motor neurons) and from them
to particular muscles. In ALS, both the upper and lower
motor neurons degenerate or die, and stop sending messages
to muscles. Unable to function, the muscles gradually weaken,
waste away (atrophy), and have very fine twitches (called
fasciculation). Eventually, the ability of the brain to start and
control voluntary movement is lost. ALS is a result of complex
array of factors, including all or just some of these like
oxidative stress, endoplasmic reticulum stress, mitochondrial
dysfunction, dysregulated endosomal trafficking, dysregulated
transcription, and RNA processing, excitotoxicity, apoptosis,
inflammation, and genetic susceptibility (Figure 1; Calvo et al.,
2014).
The diagnosis of ALS is primarily based on the symptoms,
clinical examination, and a series of tests to rule out other
diseases.We do not have a practical diagnostic biomarker for ALS
in spite of intensive research over the past several years, which
lead to diagnostic delays. Neurophysiological approaches like
motor unit number estimation (MUNE) and electromyography
(EMG), a special recording technique that detects electrical
activity in muscles, routinely play a key role in search of valid
biomarkers to recognize ALS (DeJesus-Hernandez et al., 2011;
Joyce and Carter, 2013).
Genetic Biomarkers
Mutations in more than a dozen genes have been found to cause
familial ALS. About one-third of all familial cases (and a small
percentage of sporadic cases) results from a defect in a gene
known as “chromosome 9 open reading frame 72,” or C9orf72.
The function of this gene is still unknown. Another 20 percent
of familial cases result from mutations in the gene SOD1 that
encodes the enzyme copper-zinc superoxide dismutase 1 (SOD1).
Although it is still not clear how mutations in the SOD1 gene
lead to motor neuron degeneration, there is increasing evidence
that mutant SOD1 protein can become toxic. Another 5 percent
of familial cases and <1% sporadic cases results from mutations
in the gene FUS, which encodes fused in sarcoma/translocated
in liposarcoma (FUS/TLS), and three percent of the remaining
familial cases result from mutations in TARDBP gene, which
encodes TAR DNA binding protein-43 (TDP-43; Robelin and
Gonzalez De Aguilar, 2014).
Another possibility is the role of epigenetics. Epigenetic
mechanisms modify chromatin structure and can mimic genetic
change; these modifications are reversible, heritable, and non-
heritable in DNA or chromatin structure, but not in DNA
sequence (Martin and Wong, 2013). There are different types of
epigenetic modifications, such as DNA methylation and histone
acetylation. In a study, CpG methylation microarrays were
used to profile DNA extracts of postmortem spinal cord from
sporadic ALS cases (Figueroa-Romero et al., 2012). Bisulfite-
converted DNA was amplified and hybridized to Infinium
Human Methylation27 DNA BeadChip arrays. Methylation of
27,578 CpG sites spanning 14,495 human genes was determined
and hypo- or hypermethylation 726Martin andWong was found
in 112 genes in ALS cases (Figueroa-Romero et al., 2012).
Biochemical Markers
Studies showed that the expression of themetabotropic glutamate
receptor subtypemGLUR2, which is known to provide protection
against excitotoxicity, was diminished in ALS T lymphocytes
(Poulopoulou et al., 2005), which was confirmed by the high
concentration of glutamate detected in the CSF of many patients.
The enzymatic activity of glutathione peroxidase and SOD1 was
also found to decrease in ALS erythrocytes (Cova et al., 2010).
Increased amounts of 8-hydroxy-2′-deoxyguanosine (8OH2′dG
in ALS patients, which is a product of the oxidative injury to
DNA is also a good biomarker (Bogdanov et al., 2000). There is
an uncontrolled increase of microglial cells in the central nervous
system and other immune cells, contributing to motor neuron
degeneration in ALS (Philips and Robberecht, 2011). The factors
involved in these inflammatory reactions like cytokines can be
followed in the periphery as potential biomarkers. Therefore, the
circulating levels of interleukin-6, tumor necrosis factor-α (TNF-
α), interferon-γ, monocyte chemo attractant protein-1 (MCP-1),
and wide-range C-reactive protein (wrCRP) were found to be
increased in ALS patients (Robelin and Gonzalez De Aguilar,
2014). Neurite outgrowth inhibitor (Nogo), one of the potential
biomarkers for ALS possesses axonal growth inhibitory activity
and has a central role in ALS (Fergani et al., 2005). Together with
the absence of reliable and powerful diagnostic and prognostic
biomarkers, ALS is a major cause for concern.
Frontiers in Molecular Biosciences | www.frontiersin.org 6 September 2015 | Volume 2 | Article 54
Agrawal and Biswas Biomarkers for neurodegeneration
FIGURE 1 | Different molecular pathways altered in amyotrophic lateral sclerosis, all of these deregulated mechanisms prompt motor neuron death
(Figure taken from: Calvo et al., 2014).
Huntington’s Disease
HD is a heritable neurodegenerative disorder that can affect
motor, cognitive and psychiatric functioning. Decline of
cognitive ability and change in personality are symptoms
of HD (Mastrokolias et al., 2015). The pathology is caused
by an expanded CAG repeat in the HTT gene, resulting
in a mutant huntingtin protein (mHTT). Mutant protein
aggregate formation and neuronal cell loss, with transcriptional
deregulation are prominent feature of HD brain tissue (Runne
et al., 2008). Recently, mutant huntingtin protein (mHTT)
levels were quantified by an ultrasensitive single-molecule
counting (SMC) mHTT immunoassay for the first time in
CSF samples of individuals bearing HD mutation (Wild
et al., 2015). It is important to have a disease progression
biomarker that should be able to identify changes before
clinical symptoms. Huntingtin is ubiquitously expressed and
mutant huntingtin-specific changes could be reflected by
gene expression changes in blood. Involvement of leukocytes
in immune system regulation made blood an ideal source
for identifying HD events such as peripheral inflammation.
Several studies have also identified HD blood mRNA changes
using microarray technology, but were difficult to validate
across studies (Lovrecic et al., 2009). The validation of
biomarkers for HD has been always challenging as the disease
present itself through a variety of symptoms and progression
rates.
Molecular Biomarkers
Individuals with HD over expressed the gene, H2A histone
family, member Y (H2AFY), in their blood (Hu et al., 2011).
The overexpression of this gene in both the blood and the brain
was validated in samples from clinical studies. Specifically, the
research demonstrates a 1.6-fold overexpression of H2AFY in
patients with HD. Recently a study showed gene expression
profiling, with the help of next-generation sequencing and
Fluidigm technologies and yielded a set of five genes as a
potential HD biomarkers that are highly expressed in HD blood
(Mastrokolias et al., 2015). Prokineticin 2 (PROK2) has been
proposed to have a role in the circadian rhythms alterations that
have been shown to correlate with cognitive impairment in HD
(Aziz et al., 2010). Pharmacological imposition of sleep slows
cognitive decline and reverses deregulation of PROK2 in HD
models. PROK2 is very promising biomarker of HD progression.
Evidences suggest that gene repression mechanisms are also
associated with HD and Zinc finger protein 238 (ZNF238) is a
transcriptional repressor which is involved in brain development
and myogenesis (Zhai et al., 2005). A recent gene expression
study showed that the increase in mRNA levels of Aquaporin
9 (AQP9) and presence of AQP9 in blood could represent
peripheral or central inflammatory events when accompanied
with increase in levels of four other genes (Mesko et al., 2010).
Annexin A3 (ANXA3) and Cysteine-rich, transmembrane (TM)
module (CYSTM) are two other potential biomarkers for HD
(Borovecki et al., 2005; Venancio and Aravind, 2010). ANXA3 is
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found to be up regulated in neuronal injury models and CYSTM
is involved in stress response specifically heavy metal tolerance.
Biochemical Markers
Variability in clinical phenotype of HD and potential confounds
of environmental and pharmacological factors, results in the use
of combination of different biomarkers that might be efficient in
tracking the progression of HD. Many potential biomarkers have
been identified during the discovery of disrupted homoeostasis
in HD. In a recent study, with the help of cross-sectional MRS
the researchers have distinguished putaminal metabolites in pre-
manifest and early HD individuals from controls (Sturrock et al.,
2015). It was found that the total N-acetyl aspartate (tNAA) is
lower in early HD and pre-manifest HD than in controls whereas
the gliosis marker myo-inositol (MI) was robustly elevated in
early HD. Another study, have also demonstrated metabolite
changes in the caudate nucleus and putamen of HD gene carriers
around disease onset (van Den Bogaard et al., 2014). These
correlations of Total NAA with disease burden score suggest
that this metabolite may be useful in identifying neurochemical
responses to therapeutic agents.
Vasopressin has a role in fluid balance homoeostasis, increase
in serum concentrations of vasopressin have been reported inHD
(Wood et al., 2008). Increased concentrations of 8-hydroxy-2-
deoxyguanosine (8OHdG), an indicator of oxidative DNA injury,
and increased concentrations of plasma lipid peroxide, lactic acid,
4-hydroxynoneal, and malondialdehyde in patients with HD
make them a potential biomarker (Weir et al., 2011). Decrease
in glutathione peroxidase and copper–zinc superoxide dismutase
was observed in erythrocytes from HD patients compared with
controls (Chen et al., 2007). Elevated cytokines levels including
interleukins 4, 6, 8, 10, and 23, TNF-α, and clusterin have
been identified in the post-mortem brain and plasma samples
of patients with HD (Dalrymple et al., 2007). The inflammatory
profile differences between control and gene carriers serve as
potential biochemical marker for HD including rest of the
above biomarkers. All these biomarkers would facilitate accurate
evaluation of the effectiveness of new therapies and improve the
safety and efficiency of clinical trials.
Conclusion and Future Perspective
In this short review, we have described current trends in
the applications of molecular diagnostic techniques for early
detection and diagnosis of neurodegenerative disorders
focusing on AD, PD, ALS, and HD. We have discussed
several biomolecular diagnostic markers that have been
identified in the past decade that have an enormous scope
for further research in the areas of both genetic and
biochemical molecular markers. Biomolecular diagnostic
markers may provide new insights regarding different diagnosis
and therapeutic guidance to specific neurodegenerative
diseases.
Molecular diagnostics for neurodegenerative diseases
represent a multidisciplinary research area where a robust
collaboration between neurologists, psychologists, biologist,
and biomaterials scientists and other trained personnel with the
necessary experience in managing the diseases is required. Future
research directions might include designing and developing a
combination of several biomolecular diagnostic markers for
multifunctionalities. Such amultifunctional molecular diagnostic
technology platform would significantly enhance the accuracy,
specificity and sensitivity. Developing molecular diagnostics
based on circulating miRNAs could also be a highly promising
approach for developing minimally invasive screening tests for
neurodegenerative disorders.
Future studies may also include developing a multicenter and
prospective design of molecular diagnostics tools; measurement
of multiple potential biomarkers and a prolonged clinical
follow-up period (till death as end-point) that provide
assessment of both clinical features and determinations of
the biological diagnostics and eventually neuropathological
confirmation by examining the brains of patients at
death.
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